Abstract: Ｏｂｊｅｃｔｉｖｅ：To observe the treatment response and adverse events of pomalidomide and dexamethasone(PD) in systemic light chain(AL) amyloidosis.
Ｍｅｔｈｏｄｏｌｏｇｙ：A retrospective study was conducted on AL amyloidosis patients who were treated with PD in National Clinical Research Center of kidney disease, record clinical features of these patients, analyze effect and adverse effects.
Ｒｅｓｕｌｔｓ：Two initial treated patients, 7 relapse patients, 7 refractory patients and 3 patients who were not tolerated to first line treatment were recruited. Nine (4737％) were males. The average age was 5874±1100 years. Heart and kidney involvement ratio were 3158％ and 100％. The patients received 2(1, 4) cycles of PD treatment. The total hematological response rate was 3158％ and 50％ with initial treated ones, 2857％ with refractory, 4286％ with recovery patients. The hematological response was achieved in 4 treatment cycles. As for heart response, 2(1053％) patients had progress. And 6(3158％)patients’kidney condition progressed,3(1579％)patients had partial remission, 2(1053％)had very good partial remission, 8(4211％)had no remission. The adverse events (AEs) of PD were rare and controllable, including fatigue, myelosuppression, creatinine increasing, edema and gastrointestinal reactions. The prevalence of grade 3／4 AEs was 2104％. 
Ｃｏｎｃｌｕｓｉｏｎ：Pomalidomide and dexamethasone was an effective treatment of AL amyloidosis which could help patients getting earlier hematologic response. Further observation was needed to figure out the longterm effect.